​

​

​

Year ended

​

​

​

December 31, 

​

  ​ ​ ​

  ​ ​ ​

2025

  ​ ​ ​

2024

​

​

​

​

​

​

​

​

Product revenue, net

​

​

$

642

​

$

2,266

Less:

​

​

​

​

​

​

​

Cost of goods sold

​

​

$

164

​

$

2,143

Research and development costs:

​

​

​

​

​

​

​

Personnel and related costs

​

​

$

7,196

​

$

9,796

Non-cash stock-based compensation

​

​

​

426

​

​

2,251

Professional fees

​

​

​

4,004

​

​

5,067

Clinical trials expense

​

​

​

15,433

​

​

9,384

Chemical, manufacturing and controls cost

​

​

​

1,807

​

​

1,927

Other expenses

​

​

​

1,385

​

​

2,010

Total research and development costs

​

​

$

30,251

​

$

30,435

Commercial costs:

​

​

​

​

​

​

​

Personnel and related costs

​

​

​

369

​

​

2,516

Non-cash stock-based compensation

​

​

​

—

​

​

(401)

Professional fees

​

​

​

188

​

​

554

Commercial and marketing

​

​

​

407

​

​

1,389

Travel related expenses

​

​

​

28

​

​

309

Other expenses

​

​

​

(98)

​

​

906

Total commercial costs

​

​

$

894

​

$

5,273

Selling, general and administrative costs:

​

​

​

​

​

Personnel and related costs

​

​

$

3,547

​

$

5,340

Non-cash stock-based compensation

​

​

2,341

​

​

4,306

Professional fees

​

​

10,120

​

​

15,583

Travel related expenses

​

​

​

489

​

​

446

Other expenses

​

​

3,103

​

​

3,544

Total selling, general and administrative costs

​

​

$

19,600

​

$

29,219

Restructuring costs

​

​

​

194

​

​

2,441

Total operating expenses

​

​

$

51,103

​

$

69,511

Other (income) expense

​

​

  ​

​

  ​

Interest expense

​

​

16,984

​

15,129

Interest income

​

​

​

(1,066)

​

​

(2,602)

Other (income) expense, net

​

​

​

3,518

​

​

(20,173)

Segment net loss

​

​

$

(69,897)

​

$

(59,599)

Adjustments and reconciling items

​

​

​

—

​

​

—

Consolidated Net Loss

​

​

$

(69,897)

​

$

(59,599)